{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-23-039057","form_type":"8-K","ticker":"CRSP","cik":"0001674416","company_name":"CRISPR Therapeutics AG","filed_at":"2023-08-07T23:59:59+00:00","discovered_at":"2026-05-14T18:03:34.812109+00:00","generated_at":"2026-06-12T04:27:32.156044+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"CRISPR Q2 2023 net loss $77.7M; FDA accepts exa-cel BLAs with PDUFA Dec 8 for SCD","bullets":["FDA accepted BLAs for exa-cel: Priority Review for SCD (PDUFA Dec 8, 2023), Standard Review for TDT (Mar 30, 2024).","Net loss narrowed to $77.7M from $185.8M YoY; collaboration revenue $70M from Vertex milestone.","Cash and accounts receivable $1,843M; R&D spend $101.6M, down from $123.2M Q2 2022.","Vertex licensing: $100M upfront received, $70M milestone receivable, up to $230M additional milestones.","Pipeline: CTX110/130/112/131 trials ongoing; in vivo CTX310 (ANGPTL3) enters clinic in 2023."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-23-039057","json":"https://secwatch.observer/filing/0000950170-23-039057.json","markdown":"https://secwatch.observer/filing/0000950170-23-039057.md","text":"https://secwatch.observer/filing/0000950170-23-039057.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1674416/000095017023039057/0000950170-23-039057-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1674416/000095017023039057/crsp-20230807.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-12T04:27:32.156044+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"b493bdd992027a4b08a42f96b911052a1e9dd853","claim":"CRISPR Therapeutics AG reported financial results for quarter ended June 30, 2023.","evidence_excerpt":"On August 7, 2023, CRISPR Therapeutics AG announced its financial results for the quarter ended June 30, 2023 and other business highlights.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1674416/000095017023039057/0000950170-23-039057-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"quarter ended June 30, 2023"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}